Members: Get great tips, trends and advice to living better
EmpiRx Health is hyper-focused on providing positive health experiences for you our members! We truly believe with all the complexity in the pharmacy benefits industry that your energy is best spent focused on you. Our simplified solutions ensure better health outcomes for you and your family without the hassle.
Consider us your resource! We provide you with the resources to help you take full advantage of all that your pharmacy benefit has to offer. Our goal is to educate you about how you can help to reduce costs for you and your plan sponsor, but more importantly we want to ensure that you receive the therapy you need when you need it.
We work directly with your pharmacist and physician to ensure the prescribed drug therapy meets your specific needs while allowing you to get the most out of your pharmacy benefit. We put the CARE back in pharmacy benefits.
Our member services team is available 24/7/365 to answer any questions or guide you to better understand your pharmacy benefit plan.
Have questions? Please contact us at the following:
Member Services: 1.877.241.7123 / TDD 1.888.907.0020
Register and log on to the Member Portal to view information about your benefit, check your claims history, look-up pharmacies in your network, check for lower cost drugs, or download a temporary ID card for you or your dependents.
On June 28, 2016, FDA approved Gilead’s new drug, Epclusa, to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved for use in combination with the drug ribavirin.read more
On January 28, 2016, Food and Drug Administration (FDA) has approved Merck and Co. manufactured Zepatier, a new oral treatment for adult patients with Chronic Hepatitis C (HCV) virus genotype 1 and 4 infections. Zepatier is a once a day fixed-dose oral combination...read more
What are PCSK9 Inhibitors? The Food and Drug Administration recently approved two products in a new class of cholesterol-lowering drugs known as PCSK9 Inhibitors. This class of drugs reduces the amount of low-density lipoprotein cholesterol (LDL-C), or “bad...read more